Experts say acquisitions, not Congress, will chart biotech’s course in 2020

Experts say acquisitions, not Congress, will chart biotech’s course in 2020

More reads

• Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict. (STAT Plus)
• Scientists dodge FDA to offer a $1 million anti-aging treatment in Colombia. (OneZero)
• More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill. (STAT Plus)